Abstract
Multiple cytosine guanine dinucleotides (CpG island) are found in the VIM promoter region. The levels of VIM promoter methylation and VIM gene expression were investigated in 7 cervical cancer cell lines and 50 human tissue samples with a distinctive degree of malignant trans-formation. While multiple CpG sites in the VIM promoter were highly methylated in CIN III and invasive carcinoma cells, they were rarely methylated in normal cells. Our result shows that methylation in the VIM promoter appears to start from CIN I and CIN II, relatively early stages of multistep carcinogenesis. This epigenetic alteration in VIM promoter suggests the availability as a biomarker for the early diagnosis and prevention of cervical cancer. We also show that hypermethylation in the VIM promoter is responsible for transcriptional silencing of the VIM gene in cervical cancer cells. In addition, our result shows that exogenous overexpression of the VIM gene in SiHa cervical cancer cells slightly activated cell proliferation and migration as shown in soft agar colony formation and migration assays.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agorastos, T., Miliaras, D., Lambropoulos, A.F., Chrisafi, S., Kotsis, A., Manthos, A., and Bontis, J. (2005). Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur. J. Obstet. Gynecol. Reprod. Biol. 121, 99–103.
Baylin, S.B., and Ohm, J.E. (2006). Epigenetic gene silencing in cancer — a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6, 107–116.
Bosch, F.X., Manos, M.M., Munoz, N., Sherman, M., Jansen, A.M., Peto, J., Schiffman, M.H., Moreno, V., Kurman, R., and Shah, K.V. (1995). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87, 796–802.
Chen, W.D., Han, Z.J., Skoletsky, J., Olson, J., Sah, J., and Myeroff, L. (2005). Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl. Cancer Inst. 97, 1124–1132.
Costa, V.L., Henrique, R., Danielsen, SA., Duarte-Pereira, S., Eknaes, M., Skotheim, R.I., Rodrigues, A., Magalhães, J.S., Oliveira, J., Lothe, R.A., et al. (2010). Three epigenetic biomarkers, GDF15, TMEFF2 and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 16, 5842–5851.
Durst, M., Glitz, D., Schneider, A., and Zur, H.H. (1992). Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189, 132–140.
Egger, G., Liang, G., Aparicio, A., and Jones, P.A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463.
Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. (2001). A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229.
Fuchs, E., and Weber, K. (1994). Intermediate filaments: structure, dynamics, function, and disease. Annu. Rev. Biochem. 63, 345–382.
Hu, L., Lau, S.H., Tzang, C.H., Wen, J.M., Wang, W., Xie, D., Huang, M., Wang, Y., Wu, M.C., Huang, J.F., et al. (2004). Association of Vimentin overexpression and hepatocellular car-cinoma metastasis. Oncogene 23, 298–302.
Issa, J.P. (2004). CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4, 988–993.
Ivaska, J., Pallari, H.M., Nevo, J., and Eriksson, J.E. (2007). Novel functions of vimentin in cell adhesion, migration, and signaling. Exp. Cell Res. 313, 2050–2062.
Jung, S., Jeong, D., Kim, J., Yi, L., Koo, K., Kim, C.H., Kim, C.J., and Lee, M.S. (2010). The role of hLHX6-HMR as a methylation biomarker for early diagnosis of cervical cancer. Oncology Rep. 23, 1675–1682.
Jung, S., Yi, L., Jeong, D., Kim, J., Koo, K., Lee, J., An, S., Oh, T., Kim, C.H., Kim, C.J., et al. (2011). The role of ADCYAP1, Adenylate cyclase activating polypeptide 1, as a methylation biomarker for early diagnosis of cervical cancer. Oncology Rep. 25, 245–252.
Kitamura, Y.H., Shirahata, A., Sakata, M., Goto, T., Mizukami, H., Saito, M.M., Ishibashi, K., Kigawa, G., Nemoto, H., Sanada, Y., et al. (2009). Frequent methylation of Vimentin in well-differentiated gastric carcinoma. Anticancer Res. 29, 2227–2230.
Laird, P.W. (2003). The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253–266.
Li, L.C., and Dahiya, R. (2002). MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427–1431.
Lodish, H., Baltimore, D., Berk, A., Zipursky, S.L., Mastudaira, P., and Darnell, J. (1995). Molecular cell biology, 3rd ed. (New York, USA: Scientific American Books).
McInroy, L., and Maatta, A. (2007). Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem. Biophys. Res. Commun. 360, 109–114.
Pisani, P., Parkin, D.M., Bray, F., and Ferlay, J. (1999). Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83, 870–873.
Shirahata, A., Sakata, M., Sakuraba, K., Goto, T., Mizukami, H., Saito, M., Ishibashi, K., Kigawa, G., Nemoto, H., Sanada, Y., et al. (2009). Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 29, 279–281.
Ushijima, T. (2005). Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5, 223–231.
Walboomers, J.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., Snijders, P.J., Peto, J., Meijer, C.J., and Munoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12–19.
Zur, H.H. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2, 342–350.
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Jung, S., Yi, L., Kim, J. et al. The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells 31, 405–411 (2011). https://doi.org/10.1007/s10059-011-0229-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10059-011-0229-x